Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Grapefruit USA Inc.’s (GPFT) Patented Hourglass(TM) Now Available on Blitzdirect.com

Grapefruit USA (OTCQB: GPFT), a premiere California-based cannabis and hemp company, today announced that its disruptive Hourglass(TM) time-release THC+Cannabinoid delivery cream is now available for purchase on the Blitzdirect.com (“Blitz”) mobile delivery online platform in California. Now, through Blitzdirect.com, Grapefruit’s Los Angeles customers have the option to have Hourglass delivered directly to their door. “This new Blitzdirect.com deal will not only increase the Hourglass footprint but will allow Grapefruit to reach a new segment of customers, including those unable to travel to traditional retail outlets,” said Bradley Yourist, Grapefruit CEO. “The sick, disabled, elderly or those too busy to travel can now simply order Hourglass online and have it quickly delivered directly to their home or office in California.”

To view the full press release, visit https://cnw.fm/lHMoS

About Grapefruit USA Inc.

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. For more information about the company, visit www.GrapefruitBlvd.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional results from its human clinical study HYPER-H21-2. The study was designed to evaluate the company’s proprietary DehydraTECH(TM)-processed cannabidiol (“CBD”) and its effectiveness in the treatment of hypertension. Results confirm the substance’s ability to reduce arterial stiffness and indicate potential broader applications beyond hypertension, including the treatment of cardiovascular and other diseases. According to the company, arterial stiffness can be a predictor of a variety of human diseases, including hypertension, diabetes mellitus, renal disease and more. A unique CBD formulation developed by Lexaria, DehydraTECH-CBD is based on the company’s patented and proprietary DehydraTECH drug-delivery technology. The company’s Human Study HYPER-H21-2 included 16 human volunteers aged 45 to 65 who received either a placebo or three separate doses of DehydraTECH-CBD over a 14-hour period then observed over a 24-hour period. “Reducing arterial stiffness in Lexaria’s recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery,” said Lexaria president John Docherty in the press release. “We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness.”

To view the full press release, visit https://cnw.fm/IrrMw

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by 5 to 10 times — and in some instances by as much as 27 times — compared to standard industry formulations, as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs and nonsteroidal, anti-inflammatory drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Colorado University to Study Impact of Marijuana on Exercise

Studies on the use of marijuana during exercise have produced varying findings, with one study finding that older individuals who used the herb got more exercise done when compared with those who didn’t. To make sense of the drug’s benefits, the University of Colorado Boulder plans to conduct a study that will focus on how legal market marijuana impacts performance during exercise.

The research will assess CBD (cannabidiol) and THC (tetrahydrocannabinol) and the effects these compounds have on an individual’s body during athletic performance.

Laurel Gibson, a PhD student in the institution’s Department of Psychology and Neuroscience, stated that marijuana had been linked to a decline in motivation, adding that simultaneously, researchers had seen a growing number of anecdotal reports of individuals using it in combination with everything from running and snowboarding to yoga and golfing.

Prior research in exercise neuroscience suggests that cannabinoid-like chemicals that an individual’s brain produces naturally are what cause “runner’s high” rather than endorphins. The institution will also examine whether supplementing marijuana during exercise will induce the runner’s high effect.

The research, titled the Study on Physical Activity and Cannabis Effects (“SPACE”), is currently looking for 50 volunteers who already use marijuana while exercising. The study will include three sessions.

During the first session, participants will take a baseline physical and cognitive test, where researchers will measure each individual’s heart rate. After this, each participants will be directed to go to a local dispensary and pick up either a THC-dominant strain or a CBD-dominant strain.

For the second session, each participant will be observed while they are working out when sober. During the session, participants will be required to run on the treadmill for half an hour and answer questions every 10 minutes that assess things such as the pain they’re in, what they’re thinking about and how hard the workout feels.

For the third session, each participant will again be observed while they work out, this time after using the strain they were assigned during the first session.

The researchers hope that by comparing marijuana and sober workout sessions, they can find evidence supporting the herb’s benefits for exercise. Researchers conducting the study also hope to discover other benefits of marijuana as well.

Angela Bryan, a professor at UC’s Department of Psychology and Neuroscience, stated that if marijuana could ease inflammation and pain, thereby helping older individuals to become more active, that would be a great benefit.

As the academia gets in on studying the effects of cannabis on consumers, industry actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are likely to be more credible when they share with the public what they already know about marijuana products.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Agency Head Admits No Evidence Links Occasional Cannabis Use to Harm

The road to legalizing cannabis in America has been long and tedious. Even with dozens of states now allowing medical and recreational marijuana, cannabis reform activists are still fighting. One of the toughest hurdles they have faced so far is the stigma generated from decades of anticannabis propaganda and prohibition. Cannabis legalization opponents argued that, among other things, cannabis would increase drug use among the youth, boost criminal activity, and cause a general decline in society. However, several studies on the relationship between cannabis legalization, public health, and criminal activity have revealed that these fears were largely unfounded.

During a recent interview, National Institute on Drug Abuse director Nora Volkow said she hasn’t seen any evidence that proves sporadic cannabis use by adults is harmful. Speaking with FiveThirtyEight, she said that to her knowledge there is no proof that occasional cannabis use has negative health effects. The correlation still hasn’t been tested, she said, and more research needs to be done to better understand whether using marijuana intermittently will harm your health. Volkow also mentioned that she was surprised by research indicating that cannabis users tend to have a lower body mass index (BMI).

Given how troublesome a high BMI can be people get older, she says, this is another thing researchers need to look into. Volkow’s views on cannabis are relatively progressive; while she hasn’t declared her support for broad legalization, she prefers to approach cannabis from a scientific point of view.

Thus, she acknowledges that there is currently no proof that irregular cannabis use is harmful. However, marijuana use by young people absolutely concerns her, she says, adding that consuming high-THC products on a daily basis can harm even adult brains. Still, Volkow said that youth cannabis use has not increased in the wake of state cannabis laws in an August podcast.

She emphasized the need to look at drug addiction as a public health problem rather than a criminal issue. The stigma associated with addiction and drug abuse is preventing America from dealing with its current drug crisis, she wrote in an op-ed earlier this month, and the government bears significant blame for the proliferation of this stigma. Criminal justice policies, especially the failed war on drugs, punished scores of people who had medical conditions rather than give them the treatment they needed. Policies that promoted decriminalization and increased treatment would be a much better alternative.

As leading scientists, such as the head of NIDA, speak out against the misconceptions plaguing the marijuana industry, sector players such as American Cannabis Partners could end up with a less-hostile perception of the plant they cultivate.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Focusing on Continued Growth of Top-Line Revenue, Bottom-Line Results

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has officially entered the second phase of a three-phase development strategy that captures its expansion plan in Florida after installing, commissioning and loading five of 30 planned modular grow pods, which are already growing plants. RWB, through its subsidiary Red White & Bloom Florida LLC (“RWBFL”), is fast-tracking the remaining 25 pods. Collectively, the 30 pods will provide about 19,000 square feet of operating space with an expected yield of 10,000 pounds of high-quality flower annually. RWB anticipates this annual yield will generate $30 million in additional revenue. RWBFL also successfully produced the first batch of chocolates from its new Sanderson production facility, announced in early September. A recent article reads, “The three-phased development strategy aligns perfectly with [RWB CEO Brad] Rogers’ summary of the company’s focus for the remainder of 2021 and throughout 2022. ‘The company will focus on the continued growth of our top-line revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses and the synergies from our M&A success,’ stated Rogers.”

To view the full article, visit https://cnw.fm/8yJCw

About Red White & Bloom Brands Inc.

The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Florida, Michigan, Illinois, Massachusetts, Arizona and California with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://cnw.fm/RWBYF

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Green Hygienics Holdings Inc. (GRYN) Issues 2021 Harvest and Business Development Update

Green Hygienics Holdings (OTCQB: GRYN) today provided an update on the 2021 harvest and current business development activities. According to the update, Green Hygienics has been focused on advancing several main areas of business development over the last quarter. These include its aggressive growth strategy where, to date, the company has financed its operations almost entirely through direct investment from management, and further shares have been issued instead of cash to ensure management is vested. The result is that Green Hygienics, unlike most companies in the sector, has very few shares outstanding, less than 45M fully diluted. In addition, the company announced its plans to pursue strategic acquisitions at a discount to market. As part of this effort, Green Hygienics is targeting acquisitions that are already cash flowing and have one or more aligned, established brands that the company can add supply chain or other value to. Further, in the last 24 months Green Hygienics has demonstrated its ability to cultivate premium quality hemp cost effectively and with the extraordinary potential to scale. This year’s harvest was double that of last year and will continue to grow with increasing demand as the company secures sales and distribution channels. The update also discussed the company’s engagement of a new external accounting firm from San Diego, AWICPA. The firm will manage payroll, develop policies, procedures and internal controls to manage inventory and accounts payable as well as adjust records to reflect Generally Accepted Accounting Principles (“GAAP”). Finally, in addition to the potential for revenue growth a material financing or acquisition may provide, Green Hygienics intends to launch four e-commerce websites in the first two quarters of 2022 to generate critical cash flow.

To view the full press release, visit https://cnw.fm/J9Vlq

About Green Hygienics Holdings Inc.

“Hygienics” is the science of preserving and promoting the health of individuals, communities and the planet; it’s the company’s core mission and at the heart of every decision it makes. As more and more consumers prioritize their health and demand transparency and integrity from the companies that create their products, Green Hygienics will be recognized as the most reliable, safe and secure choice in the market for CBD and hemp products. To deliver on this promise, Green Hygienics maintains a constant commitment to sustainable farming practices, cutting-edge science and industry-leading certifiability. Generating peak value from a plant of this caliber requires prioritizing innovative processing methods and impeccable attention to detail. Creating a secure supply chain and reliable long-term source for high-grade CBD is a corporate strategy for Green Hygienics, coupled with a mission to preserve and protect a valuable natural resource. As Green Hygienics evolves and expands, its path is clear and uncompromised, creating pure, non-psychoactive, nutraceutical, pharmaceutical, topical and industrial products from the highly sustainable hemp plant to benefit people and preserve the planet. For more information, visit the company’s website at www.GreenHygienics.com.

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://cnw.fm/GRYN

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that it is participating in the Benzinga Global Small Cap Conference. The premier two-day virtual event is scheduled for Dec. 8–9, 2021. The company encourages shareholders and other interested parties to attend the event and learn more about investment opportunities within the global small cap space. The conference is designed to bridges the gap between small cap companies, investors and traders. The event provides an ideal environment to learn about small cap investing. The conference agenda features insightful educational modules and provides a clear look at a curated group of small cap investment opportunities. In addition, the event provides opportunities to interact with the global small cap audience in an intimate, virtual setting.

To view the full event, visit https://cnw.fm/1msF3

To view the full press release, visit https://cnw.fm/e0FpY

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by 5 to 10 times as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs and nonsteroidal, anti-inflammatory drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — CDC Releases Advice to Employers on Cannabis Policy Formulation

The state-legal cannabis industry is in a precarious position. With that in mind, the Centers for Disease Control and Prevention (“CDC”) has offered guidance on how businesses can develop cannabis policies that adhere to state regulations but reduce the risk of impaired driving.

While federal law still classifies cannabis as a Schedule I substance with no accepted medical use and a high potential for abuse, 36 states have legalized medical cannabis and 19 states allow recreational use. On top of that, there is still no accurate way to test for THC. The level of THC in the bloodstream doesn’t always correspond with the level of impairment; tests have found that THC can stay for up to 90 days in the body. For employees who consume marijuana, especially those who operate vehicles for a living, this can have significant consequences

The CDC acknowledged that although driving under the influence of cannabis is inherently risky, different state policies and the absence of an accurate THC impairment testing tool make the issue more nuanced. Cannabis is the second-most-found drug in post-crash tests, the CDC writes in a recent blog, emphasizing that it impairs cognitive abilities and slows motor functions.

Drivers under the influence of THC have slower reaction times and reduced decision making, says the CDC, and studies have shown that accident risk increases with marijuana consumption. However, we still cannot determine the exact correlation between marijuana use and crash risk as THC can be detected in body fluids weeks after being consumed. To walk the fine line between kowtowing to state cannabis policies and preventing accidents due to impaired driving, the CDC advises employers to develop an exhaustive marijuana policy that considers the policies of the states where they operate.

It may not be possible to pass a zero-tolerance policy, the CDC says, but employers can prohibit marijuana use at work and ban their employees from reporting to work while under the influence. The CDC also advises partnering with a lawyer who is familiar with marijuana laws to review marijuana policies and offer legal feedback. In addition, the policy should outline the conditions under which drug testing will happen, the level of THC that constitutes impairment and the repercussions of a positive test.

Employers should also talk to their employees about the implications of mislabeled CBD products, specifically regarding products with higher levels of THC than what is displayed on the label. The CDC also advised employers to grant employees with drug problems access to support, such as in-house programs or referral to other resources.

The step taken by the CDC to provide marijuana policy guidance to employers is one more step to making it easier for patients who need medical marijuana to use it without fear of putting their jobs at risk. In addition, the existence of IoT marijuana-dosing devices, such as those produced by RYAH Group Inc. (CSE: RYAH), eases the task of adhering to the dosage instructions recommended by professionals.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Trial on Marijuana Drug Effectiveness in Brain Cancer Treatment Receives Clearance

The Brain Tumor Charity recently announced that it had received clearance to conduct a trial to evaluate the effectiveness of a marijuana-based drug in the treatment of recurrent glioblastoma. The general public supported a campaign to raise £400,000 ($532,000) for the charity, which would finance the three-year trial.

The research, which will be led by a University of Leeds expert, will examine whether incorporating the use of an oral spray called Sativex, which contains cannabinoids, in chemotherapy could prolong life for individuals who have been diagnosed with recurrent glioblastoma. This is in addition to evaluating whether the addition of the cannabinoid spray to chemotherapy will improve patient quality of life and/or delay the disease’s progression.

The average rate of survival after diagnosis for this aggressive type of brain cancer, even after patients undergo intensive treatment, is 12 to 18 months. Research has shown that this aggressive form of cancer is common, with figures showing that more than 2,000 individuals are diagnosed with this form of brain cancer annually in England.

The rate of growth of glioblastomas is also high in comparison to other cancers, with researchers finding that for untreated glioblastomas, the rate was 1.4% per day.

The trial plans to recruit 230 patients from 15 hospitals across the United Kingdom early in 2022. University of Leeds Professor Susan Short, who is the principal investigator on the study, stated that the treatment of glioblastomas was challenging. Short, who has majored in neuro-oncology and clinical oncology, explained that even with chemotherapy, radiotherapy and surgery, almost all of these brain tumors regrew in a year, noting that this meant that patients were left with few options.

Short highlighted the growing interest in cannabinoids and their use in various cancers, adding that these compounds had well-described effects in the brain. In addition, Short explained that research had shown that glioblastoma brain tumors had receptors to cannabinoids on their cell surface, citing lab studies which had demonstrated that cannabinoid-based drugs worked well when added to temozolomide chemotherapy and could slow tumor growth. The researchers added that they were excited to add to these previous findings and evaluate whether the drug could extend the lives of glioblastoma patients.

Brain Tumor Charity’s interim chief executive Dr. David Jenkinson asserted that researchers were excited to conduct this world-first trial in the United Kingdom. In addition to having Olympic champion Tom Daley back the trial, Leeds Hospital Charity donated £45,000 ($60,000) to the campaign.

This trial could add further credence to the existence of medicinal cannabis products manufactured by companies such as Simply Sonoma Inc.

NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Why Marijuana Company of America Inc. (MCOA) Is ‘One to Watch’

Marijuana Company of America (OTC: MCOA), which operates and invests in the cannabis sector directly, continues to grow its business. MCOA focuses on remaining fiscally conscious while further establishing itself in the legalized THC, hemp and CBD industries by offering unique exposure to the global cannabidiol sector. “The company intends to continue to leverage its premium brand hemp-based products with investments in and collaboration with existing and new strategic partners,” reads a recent article. “MCOA strives to develop a comprehensive selection of synergistic companies that provides consistent value to its shareholders. Furthermore, its vertically integrated business model provides companies and partners with the best opportunities for rapid growth. It is MCOA’s attention to detail in producing premium products and adhering to the best business practices that distinguish it among the leaders of cannabis products in the global marketplace.”

To view the full article, visit https://cnw.fm/C0IoU

About Marijuana Company of America Inc.

Marijuana Company of America operates and invests in the cannabis sector directly. The company’s operations include C-Distro, one of the fastest growing distribution companies in the THC, Hemp and CBD cannabis industries, hempsmart(TM), a premium CBD company, and a Salinas, California-based cannabis nursery cultivation facility that is a cultivator and distributor utilizing its own growing systems to produce desirable cannabis clones. The company’s core mission is to leverage its experience and access to capital to identify and invest in acquisitions with unique growth potential. For more information, visit www.MarijuanaCompanyofAmerica.com.

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://cnw.fm/MCOA

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.